Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Reg Roundup: Updates From China, Taiwan And Korea

Executive Summary

An end-of-year flurry of regulatory activity in the Asian medtech markets has kept industry on its toes, with initiatives in China, Taiwan and Korea, among other regions. But as Asia Regulatory Professional Association (ARPA) Secretary Jack Wong and ARQon consultant May Ng observe in this December update for Medtech Insight, governments and companies in certain markets might benefit from a little more pressure in view of the regulatory tasks they face.

You may also be interested in...



South Korea Roundup: Augmented Reality Device Guidelines, Digital, UDI And IVD Updates

The devices regulator has sought private sector input in updating AR/VR guidelines, but needs to do more on telemedicine integration. Mixed experiences are reported on UDI and the new IVD regulation.

GDP And UDI On List Of Regulatory Changes Under Taiwan Medical Device Act

Taiwan’s Medical Device Act was enforced on 1 May, bringing changes to good distribution practice and laying the foundation for UDI regulations.

UDI Requirements Come to Brazil

A new regulation from Brazilian device regulator ANVISA will require some high-risk devices to carry Unique Device Identifiers. The rule, which will come into effect in 2020, is the first time the country has mandated UDIs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel